Drug news
NICE recommends Xofigo for treatment of Prostate Cancer-Bayer HealthCare
The National Institute for Health and Care Excellence (NICE) has now recommended Xofigo (radium 223) a radio-pharmaceutical from Bayer HealthCare following failure of docetaxel therapy, to treat adults with hormone relapsed Prostate Cancer, symptomatic bone metastases and no known visceral metastases subject to a discount to be agreed with Bayer.Previously the NICE had not recommended the drug due to cost considerations.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.